论文部分内容阅读
弥漫大B细胞淋巴瘤(DLBCL)是最常见的侵袭性非霍奇金淋巴瘤(NHL),R-CHOP方案(利妥昔单抗加环磷酰胺加柔红霉素加长春新碱加泼尼松)的应用已逐渐使DLBCL转变为潜在可治愈性疾病,但仍有部分患者对其不敏感,难以达到完全缓解(CR)或缓解后又复发。随着人们对DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common form of invasive non-Hodgkin’s lymphoma (NHL). R-CHOP regimen (rituximab plus cyclophosphamide plus daunorubicin plus vincristine plus Nisong) has gradually transformed DLBCL into a potentially curable disease, but some patients are still not sensitive to it and are unable to achieve complete remission (CR) or relapse after remission. With people on DLBCL